Obermatt

Fresenius

GER:FRE · DE0005785604
Health Care Providers & ServicesX-Large

360

49
EV / EBIT70
Price / Owner Earnings36
Owner Earnings Yield66
Dividend Yield94
Price/Sales55
EV / Gross Profit53
Price/Book78
Return on Capital46
Cash Return on Capital53
Return on Equity57
EBIT Margin73
Gross Profitability9
Cash Conversion49
Accruals49
Owner Earnings Margin65
Sales growth48
Profit Growth89
Long-Term EPS Growth26
Owner Earnings Growth82
Reinvestment82
Price momentum32
Debt load61
Refinancing72
Debt Payback34
Liquidity58
Analyst ratings67
Opinion Changes57
Price Target Upside82
Market mood72
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fresenius clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryGermany
IndustryHealth Care Providers & Services
SizeX-Large
TypePublic Company
ExchangeXTRA
Founded2011
Employees1,453
ISINDE0005785604
Last UpdateApr 2, 2026
Themes
Chronic DiseasesHealth DiagnosticsSurgeryNephrologyHealth CareHospitalMedical

Description

Fresenius SE & Co. KGaA is a globally integrated healthcare group that provides a wide range of products and services for patients, hospitals, and healthcare providers. Business Segments The company operates through multiple key segments: Fresen…

Analysis

Middle-of-the-road

Fresenius SE & Co. KGaA is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 18.5× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 5% yearly growth; analysts expect 6%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

57

Jan 2023

Average rank

87

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
55
71
77
91
Price/Earnings
79
90
90
97
Price/Book
78
84
88
93
Dividend Yield
94
65
80
88
Value (overall)
90
78
92
96

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fresenius with its peers
Fresenius Medical Care
GER:FME
31
CountryGermany
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Bastide Le Confort Medical
PAR:BLC
64
CountryFrance
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Athens Medical Center
ATH:IATR
7
CountryGreece
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Grifols
MCE:GRF
61
CountrySpain
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Siemens Healthineers
GER:SHL
17
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Emeis
PAR:EMEIS
15
CountryFrance
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →